Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
FDA approves new CAR-T competitor to Gilead’s Tecartus
1 天前 · Called Aucatzyl, the CAR-T was developed by U.K.-based Autolus Therapeutics to treat people with B-cell precursor acute lymphoblastic leukemia whose disease has progressed following treatment with chemotherapy and other medicines. Aucatzyl will compete with Gilead Sciences’ Tecartus, which won approval in the same condition in 2021.
GSK to pay $300M to license drug it sees as potential lupus …
2024年10月29日 · GSK will pay $300 million to acquire a bispecific antibody from Shanghai-based Chimagen Biosciences that it believes has the potential to treat autoimmune diseases like lupus. The drug, which is currently in Phase 1 testing for cancer in the U.S. and China, is what’s known as a “T cell engager.”. It binds to two cell surface proteins ...
Pharma News | BioPharma Dive
6 天之前 · GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar. The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy. By BioPharma Dive staff • Oct. 25, 2024.
Gene Therapy News - BioPharma Dive
2024年11月5日 · Gene therapy startup emerges with green light for first-of-its-kind trial. Spun out of research at Nationwide Children’s Hospital, Vironexis claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses commonly used in genetic medicines. By Kristin Jensen • Sept. 12, 2024.
Biotech News - BioPharma Dive
4 天之前 · A new biotech, built around protein design, springs from David Baker’s lab. Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital. By Gwendolyn Wu • Oct. 30, 2024.
Biotech M&A has plateaued. Track the deals that are happening …
2024年10月28日 · The state of biosimilars in 2024. The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more ...
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
2024年10月24日 · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Clinical Trial News - BioPharma Dive
2024年11月4日 · Learn how optimal NGS solutions can help developers overcome challenges throughout targeted therapeutic development and the value of an end-to-end partner to help every step of the way. Sept. 30, 2024. The latest clinical trial …